Re-Evaluating the Transplant Glomerulopathy Lesion-Beyond Donor-Specific Antibodies

Transpl Int. 2024 Nov 21:37:13365. doi: 10.3389/ti.2024.13365. eCollection 2024.

Abstract

There have been significant advances in short-term outcomes in renal transplantation. However, longer-term graft survival has improved only minimally. After the first post-transplant year, it has been estimated that chronic allograft damage is responsible for 5% of graft loss per year. Transplant glomerulopathy (TG), a unique morphologic lesion, is reported to accompany progressive chronic allograft dysfunction in many cases. While not constituting a specific etiologic diagnosis, TG is primarily considered as a histologic manifestation of ongoing allo-immune damage from donor-specific anti-HLA alloantibodies (DSA). In this review article, we re-evaluate the existing literature on TG, with particular emphasis on the role of non-HLA-antibodies and complement-mediated injury, cell-mediated immune mechanisms, and early podocyte stress in the pathogenesis of Transplant Glomerulopathy.

Keywords: C4d; anti HLA antibodies; banff criteria; podocyte; transplant glomerulopathy (TG).

Publication types

  • Review

MeSH terms

  • Graft Rejection / immunology
  • Graft Survival / immunology
  • HLA Antigens* / immunology
  • Humans
  • Isoantibodies* / immunology
  • Kidney Glomerulus / immunology
  • Kidney Glomerulus / pathology
  • Kidney Transplantation* / adverse effects
  • Podocytes / immunology
  • Podocytes / pathology
  • Tissue Donors

Substances

  • Isoantibodies
  • HLA Antigens

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.